About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Analysts see over 50% gains in these 2 mid-cap biotech stocks

Biotech stocks for 2024

2024 is shaping up to be a pivotal year for the biotechnology industry.

In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way drugs are developed and health care is administered. Advancements in the treatment of cancer, Alzheimer’s disease and obesity have highlighted steady progress in the field. 

This year, biotech companies are expected to build off last year’s breakthroughs and embrace emerging trends. Not surprisingly, artificial intelligence (AI) is poised to play a big role in drug and protein discovery. RNA technologies are expected to become more sophisticated and have a bigger impact on cancer and HIV treatment. CRISPR technology that uses specific delivery systems to target various diseases is gaining momentum.

With these and other trends expected to drive life-changing discoveries, biotech will be an exciting group to watch in 2024. Combined with recent clinical trial successes, the outlook for growth has made biotech one of the hottest investments of late. 

Over the last three months, U.S. biotech stocks are up approximately 15% and have outperformed the broader healthcare sector. If the market’s ‘risk-on’ sentiment persists, volatile biotech shares could continue to deliver outsized gains.

This month, bullish pipeline news, analyst commentary and M&A deals have sparked rallies in multiple mid-cap biotech names. ImmunityBio and CymaBay Therapeutics are just two examples. 

But with these and other stocks trading near highs, companies recovering from 52-week lows could have more explosive upside. Wall Street sees big comeback gains ahead in these two biotechs.

Why are analysts bullish on MDGL? 

Last week, five Wall Street analysts issued buy ratings on Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). Their average price target is $332.50, which implies 54% upside from Monday’s close. 

The bullish endorsement came after the biopharma company published positive Phase 3 trial results for its investigational drug resmetirom for the treatment of nonalcoholic steatohepatitis (NASH). Madrigal’s lead candidate achieved both of the study’s primary endpoints and demonstrated a favorable safety profile. The FDA granted resmetirom Priority Review and set March 14, 2024 as the target date to complete its review. If approved, it would become the first medicine approved for NASH, a disease that affects an estimated 1.5 million U.S. patients. 

Madrigal’s potential to improve the lives of Americans diagnosed with NASH and other liver diseases could not only lead to strong financial results but also make it an attractive acquisition target to a larger biotech company. The stock price rose to $322.67 in May 2023 but has since pulled back by more than $100.00.

What is the consensus price target on BEAM?

Over the last three months, price targets on Beam Therapeutics Inc. (NASDAQ: BEAM) have averaged $55.00. Shares of the precision genetic medicines developer jumped 15% on Monday despite an absence of company news. Gilead Sciences announced the acquisition of mid-cap biotech CymaBay Therapeutics, sparking speculation that the similarly-sized Beam Therapeutics could be a target as industry M&A activity heats up. 

In spite of the surge, BEAM sits more than 60% away from Wall Street’s consensus price target. Two weeks ago, J.P. Morgan upgraded Beam Therapeutics from Neutral to Overweight, becoming the fifth consecutive firm to call the stock a buy in 2024.

Earlier this year, the company reported progress across its hematology and genetic disease portfolio in addition to outlining anticipated trial milestones around its sickle cell disease (SCD) and genetic disease franchises. Initial data from the BEACON trial for investigational SCD cell therapy BEAM-101 is expected to be released in the second half of 2024. The first clinical trial for genetic disease candidate BEAM-302 could begin as early as the first half of 2024.

Given Beam Therapeutics’ advancing pipeline and potential to reshape the gene editing landscape, its stock has returned to traders’ radar after slipping as low as $16.95 in October 2023. BEAM also garners a lot of attention because it is a top 20 holding of famed portfolio manager Cathie Wood’s ARK Innovation ETF (ARKK). ARKK contains several other promising biotech names, including CRISPR Therapeutics and Intellia Therapeutics.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.